Core Insights - RaySearch Laboratories reported a decline in order intake and net sales for the second quarter of 2025 compared to the same period in 2024, with order intake at SEK 241.2 million (down from 290.3 million) and net sales at SEK 304.9 million (down from 318.9 million) [6] - The company experienced a significant drop in operating profit, which amounted to SEK 36.4 million (compared to 79.3 million) and profit after tax at SEK 30.8 million (down from 61.4 million) [6] - Despite the challenges in the second quarter, the half-year results showed an increase in order intake to SEK 650.8 million (up from 528.8 million) and net sales at SEK 636.6 million (up from 576.1 million) [6] Financial Performance - For the second quarter, earnings per share before and after dilution were SEK 0.90 (down from 1.79) [6] - Cash flow from operating activities for the second quarter was SEK 70.6 million (down from 154.6 million) [6] - The order backlog at the end of the second quarter was SEK 1,665.3 million (down from 1,790.5 million) [6] Significant Events - RaySearch launched RayStation v2025 in May, which includes machine learning capabilities for automated treatment planning and support for upright patient treatment planning [6] - The Royal Marsden in the UK became the first clinic to use the new adaptive re-planning module in RayStation during online adaptive radiotherapy [6] - A strategic partnership was announced with Radiology Oncology Systems, Inc. to integrate refurbished linear accelerators with advanced software solutions [6] Company Overview - RaySearch Laboratories AB is a medical technology company focused on developing software solutions for cancer treatment, including RayStation and RayCare systems [7] - The company has sold its software to over 1,100 clinics across 47 countries since its founding in 2000 [8]